AC Immune Beefs Up Neurodegenerative Diseases Pipeline
The Swiss biotech, AC Immune, has identified further antibodies aimed at targets in neurodegenerative diseases that could complement its work in beta-amyloid and tau-based approaches to conditions like Alzheimer's disease.
You may also be interested in...
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
The deal, worth up to $400m, will see the companies develop an early-stage alpha-synuclein antibody, a hot area of research in Parkinson's disease.
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.